Devonian Health Group Inc. (CVE:GSD – Get Free Report)’s stock price was down 8.4% on Thursday. The company traded as low as C$8.20 and last traded at C$8.20. Approximately 2,207 shares changed hands during trading, an increase of 33% from the average session volume of 1,662 shares. The stock had previously closed at C$8.95.
Devonian Health Group Price Performance
The company has a debt-to-equity ratio of 16.36, a quick ratio of 7.82 and a current ratio of 1.07. The stock’s fifty day moving average price is C$9.10 and its 200-day moving average price is C$9.97. The firm has a market cap of C$22.25 million, a PE ratio of -3.56 and a beta of 0.03.
About Devonian Health Group
Devonian Health Group Inc engages in the development of botanical drugs. Its lead product candidate is Thykamine, completed Phase IIa clinical trial product for the treatment of ulcerative colitis and atopic dermatitis. The company also develops Pantoprazole Magnesium for the treatment of gastric; Cleo-35 for the treatment of hormonal acne in women; and value-added products for dermo-cosmetics. In addition, the company acquires drug and health product licenses; and distributes pharmaceutical products.
See Also
- Five stocks we like better than Devonian Health Group
- Conagra’s Turnaround Is Starting to Show Up in the Numbers
- MarketBeat Week in Review – 09/28 – 10/02
- AST SpaceMobile’s BlueBird Progress Comes With Several Risks Still Unresolved
- Time to Nibble on MCD Stock After it Enters Oversold Territory?
Receive News & Ratings for Devonian Health Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Devonian Health Group and related companies with MarketBeat.com's FREE daily email newsletter.
